参考文献/References:
[1] Ziadi MC, Dekemp RA, Williams KA, et al. Impaired myocardial flow reserve on rubidium-82 positron emission tomography imaging predicts adverse outcomes in patients assessed for myocardial ischemia[J]. J Am Coll Cardiol, 2011, 58 (7):740-748. DOI:10.1016/j.jacc.2011.01.065.
[2] Murthy VL, Naya M, Foster CR, et al. Improved cardiac risk assessment with noninvasive measures of coronary flow reserve[J]. Circulation, 2011, 124 (20):2215-2224. DOI:10.1161/CIRCULA-TIONAHA.111.050427.
[3] Taqueti VR, Everett BM, Murthy VL, et al. Interaction of impaired coronary flow reserve and cardiomyocyte injury on adverse cardiovascular outcomes in patients without overt coronary artery disease[J]. Circulation, 2015, 131 (6):528-535. DOI:10.1161/CIRCULATIONAHA.114.009716.
[4] Dean J, Cruz SD, Mehta PK, et al. Coronary microvascular dysfunction:sex-specific risk, diagnosis, and therapy[J]. Nat Rev Cardiol, 2015, 12 (7):406-414. DOI:10.1038/nrcardio.2015.72.
[5] Pries AR, Reglin B. Coronary microcirculatory pathophysiology:can we afford it to remain a black box?[J]. Eur Heart J, 2017, 38 (7):478-488. DOI:10.1093/eurheartj/ehv760.
[6] Cannon RO, Epstein SE. "Microvascular angina" as a cause of chest pain with angiographically normal coronary arteries[J]. Am J Cardiol, 1988, 61 (15):1338-1343.
[7] Crea F, Camici PG, Bairey MCN. Coronary microvascular dysfunction:an update[J]. Eur Heart J, 2014, 35 (17):1101-1111. DOI:10.1093/eurheartj/eht513.
[8] Shome JS, Perera D, Plein S, et al. Current perspectives in coronary microvascular dysfunction[J/OL]. Microcirculation, 2017, 24 (1):e12340[2018-01-14]. https://doi.org/10.1111/micc.12340. DOI:10.1111/micc.12340.
[9] Löffler AI, Bourque JM. Coronary Microvascular Dysfunction, Microvascular Angina, and Management[J]. Curr Cardiol Rep, 2016, 18 (1):1. DOI:10.1007/s11886-015-0682-9.
[10] Saraste A, Kajander S, Han C, et al. PET:Is myocardial flow quantification a clinical reality?[J]. J Nucl Cardiol, 2012, 19 (5):1044-1059. DOI:10.1007/s12350-012-9588-8.
[11] Danad I, Uusitalo V, Kero T, et al. Quantitative assessment of myocardial perfusion in the detection of significant coronary artery disease:cutoff values and diagnostic accuracy of quantitative[(15)O]H2O PET imaging[J]. J Am Coll Cardiol, 2014, 64 (14):1464-1475. DOI:10.1016/j.jacc.2014.05.069.
[12] Camici PG, d’Amati G, Rimoldi O. Coronary microvascular dysfunction:mechanisms and functional assessment[J]. Nat Rev Cardiol, 2015, 12 (1):48-62. DOI:10.1038/nrcardio.2014.160.
[13] Sciagrà R. Quantitative cardiac positron emission tomography:the time is coming![J/OL]. Scientifica (Cairo), 2012, 2012:e948653[2018-01-14]. http://dx.doi.org/10.6064/2012/948653. DOI:10.6064/2012/948653.
[14] 孙茉茉, 李剑明. PET心肌灌注显像及其定量分析的研究进展[J].国际放射医学核医学杂志, 2017, 41 (6):423-429. DOI:10.3760/cma.j.issn.1673-4114.2017.06.008. Sun MM, LI JM.The research progress of myocardial perfusion and its quantitative analysis with PET[J]. International J Radiat Med Nucl Med, 2017, 41 (6):423-429. DOI:10.3760/cma.j.issn.1673-4114.2017.06.008.
[15] Nakazato R, Heo R, Leipsic J, et al. CFR and FFR assessment with PET and CTA:strengths and limitations[J]. Curr Cardiol Rep, 2014, 16 (5):484. DOI:10.1007/s11886-014-0484-5.
[16] Al BF, Aljizeeri A, Almasoudi F, et al. Assessment of myocardial blood flow and coronary flow reserve with positron emission tomography in ischemic heart disease:current state and future directions[J]. Heart Fail Rev, 2017, 22 (4):441-453. DOI:10.1007/s10741-017-9625-4.
[17] Gould KL, Johnson NP, Bateman TM, et al. Anatomic versus physiologic assessment of coronary artery disease. Role of coronary flow reserve, fractional flow reserve, and positron emission tomography imaging in revascularization decision-making[J]. J Am Coll Cardiol, 2013, 62 (18):1639-1653. DOI:10.1016/j.jacc.2013. 07.076.
[18] von Scholten BJ, Hasbak P, Christensen TE, et al. Cardiac 82Rb PET/CT for fast and non-invasive assessment of microvascular function and structure in asymptomatic patients with type 2 diabetes[J]. Diabetologia, 2016, 59 (2):371-378. DOI:10.1007/s00125-015-3799-x.
[19] Marinescu MA, Löffler AI, Ouellette M, et al. Coronary microvascular dysfunction, microvascular angina, and treatment strategies[J]. JACC Cardiovasc Imaging, 2015, 8 (2):210-220. DOI:10.1016/j.jcmg.2014.12.008.
[20] Driessen RS, Raijmakers PG, Stuijfzand WJ, et al. Myocardial perfusion imaging with PET[J]. Int J Cardiovasc Imaging, 2017, 33 (7):1021-1031.DOI:10.1007/s10554-017-1084-4.
[21] Gulati M,Shaw LJ,Bairey Merz CN,et al. Myocardial ischemia in women:lessons from the NHLBI WISE study[J]. Clin Cardiol, 2012, 35 (3):141-148. DOI:10.1002/clc.21966.
[22] Taqueti VR, Shaw LJ, Cook NR, et al. Excess Cardiovascular Risk in Women Relative to Men Referred for Coronary Angiography Is Associated With Severely Impaired Coronary Flow Reserve, Not Obstructive Disease[J]. Circulation, 2017,135 (6):566-577. DOI:10.1161/CIRCULATIONAHA.116.023266.
[23] Marroquin OC, Holubkov R, Edmundowicz D, et al. Heterogeneity of microvascular dysfunction in women with chest pain not attributable to coronary artery disease:implications for clinical practice[J]. Am Heart J, 2003, 145 (4):628-635. DOI:10.1067/mhj.2003.95.
[24] Westergren HU, Michaëlsson E, Blomster JI, et al. Determinants of coronary flow reserve in non-diabetic patients with chest pain without myocardial perfusion defects[J/OL]. PLoS One, 2017, 12 (4):e0176511[2018-01-14]. https://doi.org/10.1371/journal.pone.0176511. DOI:10.1371/journal.pone.0176511.
[25] Di Carli MF, Janisse J, Grunberger G, et al. Role of chronic hyper-glycemia in the pathogenesis of coronary microvascular dysfunction in diabetes[J]. J Am Coll Cardiol, 2003, 41 (8):1387-1393. DOI:org/10.1016/S0735-1097 (03)00166-9.
[26] Murthy VL, Naya M, Foster CR, et al. Association between coronary vascular dysfunction and cardiac mortality in patients with and without diabetes mellitus[J]. Circulation, 2012, 126 (15):1858-1868. DOI:10.1161/CIRCULATIONAHA.112.120402.
[27] Murthy VL, Naya M, Taqueti VR, et al. Effects of sex on coronary microvascular dysfunction and cardiac outcomes[J]. Circulation, 2014, 129 (24):2518-2527. DOI:10.1161/CIRCULATIONAHA.113. 008507.
[28] Taqueti VR, Solomon SD, Shah AM, et al. Coronary microvascular dysfunction and future risk of heart failure with preserved ejection fraction[J]. Eur Heart J, 2018, 39 (10):840-849. DOI:10.1093/eurheartj/ehx721.
[29] Naya M, Murthy VL, Taqueti VR, et al. Preserved coronary flow reserve effectively excludes high-risk coronary artery disease on angiography[J]. J Nucl Med 2014, 55:248-55. 10.2967/jnumed.113.121442.
[30] Taqueti VR, Hachamovitch R, Murthy VL, et al. Global coronary flow reserve is associated with adverse cardiovascular events independently of luminal angiographic severity and modifies the effect of early revascularization[J]. Circulation, 2015, 131 (1):19-27. DOI:10.1161/CIRCULATIONAHA.114.011939.
[31] Gupta S, Gupta MM. No reflow phenomenon in percutaneous coronary interventions in ST-segment elevation myocardial infarction[J]. Indian Heart J, 2016, 68 (4):539-551. DOI:10.1016/j.ihj.2016.04.006.
[32] Brosh D, Assali AR, Mager A, et al. Effect of no-reflow during primary percutaneous coronary intervention for acute myocardial infarction on six-month mortality[J]. Am J Cardiol, 2007, 99 (4):442-445. DOI:org/10.1016/j.amjcard.2006.08.054.
相似文献/References:
[1]陈挺,张宏,田梅.18F-FDG PET/CT代谢半定量参数在非小细胞肺癌预后评估中的价值[J].国际放射医学核医学杂志,2018,(3):269.[doi:10.3760/cma.j.issn.1673-4114.2018.03.014]
Chen Ting,Zhang Hong,Tian Mei.Prognostic evaluation of patients with non-small cell lung cancer by using semi-quantitative metabolic parameters of 18F-FDG PET/CT[J].International Journal of Radiation Medicine and Nuclear Medicine,2018,(5):269.[doi:10.3760/cma.j.issn.1673-4114.2018.03.014]
[2]杜芬,胡珊,梁梦,等.18F-FDG PET/CT显像在甲状腺偶发瘤良恶性诊断中的研究进展[J].国际放射医学核医学杂志,2018,(3):274.[doi:10.3760/cma.j.issn.1673-4114.2018.03.015]
Du Fen,Hu Shan,Liang Meng,et al.Development in the diagnosis of benign and malignant thyroid incidentalomas by 18F-FDG PET/CT imaging[J].International Journal of Radiation Medicine and Nuclear Medicine,2018,(5):274.[doi:10.3760/cma.j.issn.1673-4114.2018.03.015]
[3]高之晔,韩星敏.放射性核素标记的胆碱在PET/CT肿瘤显像中的应用[J].国际放射医学核医学杂志,2018,(3):280.[doi:10.3760/cma.j.issn.1673-4114.2018.03.016]
Gao Zhiye,Han Xingmin.Application of radionuclide-labeled choline in PET/CT tumor imaging[J].International Journal of Radiation Medicine and Nuclear Medicine,2018,(5):280.[doi:10.3760/cma.j.issn.1673-4114.2018.03.016]
[4]孙晓琰,常城,雷贝,等.18F-FDG PET/CT在肺癌性淋巴管病的影像学特征及诊断价值[J].国际放射医学核医学杂志,2018,(4):295.[doi:10.3760/cma.j.issn.1673-4114.2018.04.001]
Sun Xiaoyan,Chang Cheng,Lei Bei,et al.Imaging features and diagnostic value of 18F-FDG PET/CT in pulmonary lymphangitic carcinomatosis[J].International Journal of Radiation Medicine and Nuclear Medicine,2018,(5):295.[doi:10.3760/cma.j.issn.1673-4114.2018.04.001]
[5]龚伟,于丽娟,田墨涵,等.18F-FDG PET/CT代谢参数在子宫内膜癌术前风险评估中的价值[J].国际放射医学核医学杂志,2018,(4):301.[doi:10.3760/cma.j.issn.1673-4114.2018.04.002]
Gong Wei,Yu Lijuan,Tian Mohan,et al.The value of 18F-FDG PET/CT metabolic parameters in preoperative risk stratification of endometrial carcinoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2018,(5):301.[doi:10.3760/cma.j.issn.1673-4114.2018.04.002]
[6]段晓蓓,陈相猛,黄斌豪,等.18F-FDG PET/CT显像在肾上腺转移瘤中的诊断价值和预测分析[J].国际放射医学核医学杂志,2018,(4):307.[doi:10.3760/cma.j.issn.1673-4114.2018.04.003]
Duan Xiaobei,Chen Xiangmeng,Huang Binhao,et al.18F-FDG PET/CT diagnostic value and predictive analysis in adrenal metastasis lesions[J].International Journal of Radiation Medicine and Nuclear Medicine,2018,(5):307.[doi:10.3760/cma.j.issn.1673-4114.2018.04.003]
[7]麻广宇,刘家金,徐白萱,等.11C-乙酸盐PET/CT显像在中、高分化肝细胞肝癌复发与转移监测中的应用研究[J].国际放射医学核医学杂志,2018,(4):312.[doi:10.3760/cma.j.issn.1673-4114.2018.04.004]
Ma Guangyu,Liu Jiajin,Xu Baixuan,et al.Application of 11C-acetate PET/CT imaging in the detection of recurrence and metastasis of hepatocellular carcinoma with intermediate and high differentiation[J].International Journal of Radiation Medicine and Nuclear Medicine,2018,(5):312.[doi:10.3760/cma.j.issn.1673-4114.2018.04.004]
[8]谭延林,董楚宁,王云华.18F-FDG PET/CT在肺癌疗效评估中的价值[J].国际放射医学核医学杂志,2018,(4):357.[doi:10.3760/cma.j.issn.1673-4114.2018.04.013]
Tan Yanlin,Dong Chuning,Wang Yunhua.The value of 18F-FDG PET/CT on evaluating therapeutic effect in the treatment of lung cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2018,(5):357.[doi:10.3760/cma.j.issn.1673-4114.2018.04.013]
[9]刘道佳,吴君心,唐明灯,等.18F-FLT PET/CT显像评估复发脑胶质瘤患者预后的价值[J].国际放射医学核医学杂志,2018,(5):403.[doi:10.3760/cma.j.issn.1673-4114.2018.05.003]
Liu Daojia,Wu Junxin,Tang Mingdeng,et al.Prognostic value of 18F-FLT PET/CT imaging in patients with recurrent gliomas[J].International Journal of Radiation Medicine and Nuclear Medicine,2018,(5):403.[doi:10.3760/cma.j.issn.1673-4114.2018.05.003]
[10]赵竞,张占文,马慧,等.PET/CT显像剂18F-氟丙酸在肝癌中的生物学评估[J].国际放射医学核医学杂志,2018,(5):414.[doi:10.3760/cma.j.issn.1673-4114.2018.05.005]
Zhao Jing,Zhang Zhanwen,Ma Hui,et al.Biological evaluation of PET/CT imaging agent 18F-fluoropropionic acid in hepatocellular carcinoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2018,(5):414.[doi:10.3760/cma.j.issn.1673-4114.2018.05.005]